{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:39:55Z","timestamp":1790393995647,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["212082PCR4005"],"award-info":[{"award-number":["212082PCR4005"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumor cells (CTCs) are an established prognostic marker in castration-resistant prostate cancer but have received little attention in localized high-risk disease. We studied the detection rate of CTCs in patients with high-risk prostate cancer before and after androgen deprivation therapy and radiotherapy to assess its value as a prognostic and monitoring marker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We performed a prospective analysis of CTCs in the peripheral blood of 65 treatment-na\u00efve patients with high-risk prostate cancer. EpCAM-positive CTCs were enumerated using the CELLSEARCH system at 4 timepoints. A cut off of 0 vs\u2009\u2265\u20091 CTC\/7.5\u2009ml blood was defined as a threshold for negative versus positive CTCs status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CTCs were detected in 5\/65 patients (7.5%) at diagnosis, 8\/62 (12.9%) following neoadjuvant androgen deprivation and 11\/59 (18.6%) at the end of radiotherapy, with a median CTC count\/7.5\u2009ml of 1 (range, 1\u2013136). Only 1 patient presented a positive CTC result 9\u2009months after radiotherapy. Positive CTC status (at any timepoint) was not significantly associated with any clinical or pathologic factors. However, when we analyzed variations in CTC patterns following treatment, we observed a significant association between conversion of CTCs and stages T3 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.044) and N1 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). Detection of CTCs was not significantly associated with overall survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.40).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study showed a low detection rate for CTCs in patients with locally advanced high-risk prostate cancer. The finding of a de novo positive CTC count after androgen deprivation therapy is probably due to a passive mechanism associated with the destruction of the tumor. Further studies with larger samples and based on more accurate detection of CTCs are needed to determine the potential prognostic and therapeutic value of this approach in non-metastatic prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01800058?term=CTCs%2C+radiotherapy&amp;cond=Prostate+Cancer&amp;cntry=ES&amp;city=Madrid&amp;draw=2&amp;rank=1\">NCT01800058<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-020-01577-5","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T14:05:26Z","timestamp":1591106726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-2312","authenticated-orcid":false,"given":"Almudena","family":"Zapatero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"G\u00f3mez-Caama\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Cabeza Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Muinelo-Romay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Martin de Vidales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Abalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Calvo Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Leon Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena Vega","family":"Vega Piris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"issue":"15","key":"1577_CR1","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","volume":"34","author":"M Bolla","year":"2016","unstructured":"Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans P, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate Cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748\u201356.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1577_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"337","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J Med. 2017;337(4):338\u201351.","journal-title":"N Engl J Med"},{"key":"1577_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"issue":"7","key":"1577_CR4","first-page":"2073","volume":"8","author":"T Fehm","year":"2002","unstructured":"Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002 Jul;8(7):2073\u201384.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1577_CR5","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","volume":"13","author":"DC Danila","year":"2007","unstructured":"Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13(23):7053\u20137.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1577_CR6","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1577_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/annonc\/mdn544","volume":"20","author":"D Olmos","year":"2009","unstructured":"Olmos D, Arkenau H, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-Centre experience. Ann Oncol. 2009;20(1):27\u201333.","journal-title":"Ann Oncol"},{"issue":"3","key":"1577_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","volume":"10","author":"HI Scher","year":"2009","unstructured":"Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10(3):233\u20139.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1577_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","volume":"36","author":"G Heller","year":"2018","unstructured":"Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate Cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol. 2018;36(6):572\u201380.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1577_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","volume":"70","author":"D Lorente","year":"2016","unstructured":"Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate Cancer. Eur Urol. 2016;70(6):985\u201392.","journal-title":"Eur Urol"},{"issue":"6","key":"1577_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.juro.2018.01.033","volume":"199","author":"HJ Chalfin","year":"2018","unstructured":"Chalfin HJ, Glavaris SA, Malihi PD, Sperger JM, Gorin MA, Lu C, et al. Prostate Cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms. J Urol. 2018;199(6):1494\u2013501.","journal-title":"J Urol"},{"key":"1577_CR12","doi-asserted-by":"crossref","unstructured":"Tsumura H, Satoh T, Ishiyama H, Tabata K, Takenaka K, Sekiguchi A, et al. Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer. Int J Mol Sci. 2017;18(1).","DOI":"10.3390\/ijms18010128"},{"key":"1577_CR13","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.juro.2008.01.102","volume":"179","author":"JW Davis","year":"2008","unstructured":"Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008;179:2187\u201391.","journal-title":"J Urol"},{"issue":"10","key":"1577_CR14","first-page":"5679","volume":"35","author":"M Thalgott","year":"2015","unstructured":"Thalgott M, Rack B, Horn T, Heck MM, Eiber M, K\u00fcbler H, et al. Detection of circulating tumor cells in locally advanced high-risk prostate Cancer during Neoadjuvant chemotherapy and radical prostatectomy. Anticancer Res. 2015;35(10):5679\u201385.","journal-title":"Anticancer Res"},{"issue":"12","key":"1577_CR15","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00432-014-1775-3","volume":"140","author":"J Loh","year":"2014","unstructured":"Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, et al. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol. 2014;140(12):2157\u201362.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1577_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0090-4295(02)02581-5","volume":"61","author":"RM Gewanter","year":"2003","unstructured":"Gewanter RM, Katz AE, Olsson CA, Benson MC, Singh A, Schiff PB, et al. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology. 2003;61(5):967\u201371.","journal-title":"Urology"},{"issue":"3\u20134","key":"1577_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2119\/molmed.2008.00116","volume":"15","author":"Z Panteleakou","year":"2009","unstructured":"Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, et al. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med. 2009;15(3\u20134):101\u201314.","journal-title":"Mol Med"},{"issue":"11","key":"1577_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.urolonc.2016.09.001","volume":"34","author":"DT Miyamoto","year":"2016","unstructured":"Miyamoto DT, Lee RJ. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: tools for real-time precision medicine? Urol Oncol. 2016;34(11):490\u2013501.","journal-title":"Urol Oncol"},{"issue":"2","key":"1577_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrurol.2016.224","volume":"14","author":"MA Gorin","year":"2017","unstructured":"Gorin MA, Verdone JE, Van der Toom E, Bivalacqua TJ, Allaf ME, Pienta KJ. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nat Rev Urol. 2017;14(2):90\u20137.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"1577_CR20","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","volume":"32","author":"A Goldkorn","year":"2014","unstructured":"Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32(11):1136\u201342.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1577_CR21","first-page":"2881","volume":"13","author":"Y Zheng","year":"2016","unstructured":"Zheng Y, Zhang C, Wu J, Cheng G, Yang H, Hua L, et al. Prognostic value of circulating tumor cells in castration resistant prostate Cancer: a meta-analysis. Urol J. 2016;13(6):2881\u20138.","journal-title":"Urol J"},{"issue":"12","key":"1577_CR22","doi-asserted-by":"publisher","first-page":"e0144535","DOI":"10.1371\/journal.pone.0144535","volume":"10","author":"H Schneck","year":"2015","unstructured":"Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH, et al. EpCAM-independent enrichment of circulating tumor cells in metastatic breast Cancer. PLoS One. 2015;10(12):e0144535.","journal-title":"PLoS One"},{"issue":"8","key":"1577_CR23","doi-asserted-by":"publisher","first-page":"e0158354","DOI":"10.1371\/journal.pone.0158354","volume":"11","author":"G Theil","year":"2016","unstructured":"Theil G, Fischer K, Weber E, Medek R, Hoda R, L\u00fccke K, et al. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study. PLoS One. 2016;11(8):e0158354.","journal-title":"PLoS One"},{"key":"1577_CR24","doi-asserted-by":"publisher","first-page":"39736","DOI":"10.1038\/srep39736","volume":"6","author":"A Kuske","year":"2016","unstructured":"Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Prei\u00dfer F, et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci Rep. 2016;6:39736.","journal-title":"Sci Rep"},{"issue":"25","key":"1577_CR25","doi-asserted-by":"publisher","first-page":"25ra23","DOI":"10.1126\/scitranslmed.3000403","volume":"2","author":"SL Stott","year":"2010","unstructured":"Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010;2(25):25ra23.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1577_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.urolonc.2015.12.003","volume":"34","author":"CP Meyer","year":"2016","unstructured":"Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, et al. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol. 2016;34(5):235 e11\u20136.","journal-title":"Urol Oncol"},{"issue":"2","key":"1577_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clgc.2014.08.014","volume":"13","author":"SK Pal","year":"2015","unstructured":"Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, et al. Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer. 2015;13(2):130\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"1577_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JU.0000000000000393","volume":"202","author":"TW Friedlander","year":"2019","unstructured":"Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, et al. Identification and characterization of circulating tumor cells in men who have undergone prostatectomy for clinically localized, high risk prostate Cancer. J Urol. 2019;202:732\u201341.","journal-title":"J Urol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01577-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T19:12:12Z","timestamp":1622488332000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01577-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01577-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23584\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"12 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethics Committee in Clinical Research of Hospital Universitario de La Princesa, reference number 2045.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Other than the grant from Janssen-Cilag, the authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}